Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
The composition of the intestinal microbiota influences the development of inflammatory disorders. However, associating inflammatory diseases with specific microbial members of the microbiota is challenging, because clinically detectable inflammation and its treatment can alter the microbiota's composition. Immunologic checkpoint blockade with ipilimumab, a monoclonal antibody that blocks cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) signalling, is associated with new-onset, immune-mediated colitis. Here we conduct a prospective study of patients with metastatic melanoma undergoing ipilimumab treatment and correlate the pre-inflammation faecal microbiota and microbiome composition with subsequent colitis development. We demonstrate that increased representation of bacteria belonging to the Bacteroidetes phylum is correlated with resistance to the development of checkpoint-blockade-induced colitis. Furthermore, a paucity of genetic pathways involved in polyamine transport and B vitamin biosynthesis is associated with an increased risk of colitis. Identification of these biomarkers may enable interventions to reduce the risk of inflammatory complications following cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In parallel to microbial therapeutics, microbial signatures are being evaluated as a novel class of biomarkers, applied for stratification of efficacy and safety in clinical trials across multiple indications (Ananthakrishnan et al., 2017; Dubin et al., 2016).”
From Gut microbiome stability and dynamics in healthy donors and patients with non-gastrointestinal cancers (2021) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of the microbiome to generate polyamines has also been associated with reduced toxicity of antibody to CTLA-4 in melanoma patients (22).”
From The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies (2018) · cites this paper as [22]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“differences may be related to several different factors – including differences in techniques used to analyze samples and reference databases used for analysis – which varied widely across the studies”
From The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy (2018) · cites this paper as Dubin et al., 2016
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“CTLA-4 blockade (alone or in combination with anti-PD-1/PD-L1) produces toxicities in a dose-dependent fashion.22,23”
From Endocrine toxicities of immune checkpoint inhibitors (2021) · cites this paper as [22]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, there is evidence that the microbiome is associated with development of immune-related adverse events (irAEs) following ICB7–9.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [8]
14 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Self-citationAdverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationUCHIME improves sensitivity and speed of chimera detection
Edgar, R. C., Haas, B. J., Clemente, J. C., Quince, C., & Knight, R. (2011) · Bioinformatics · doi:10.1093/bioinformatics/btr381 · Cited by 15,114
Structure, function and diversity of the healthy human microbiome
The Human Microbiome Project Consortium (2012) · Nature · doi:10.1038/nature11234 · Cited by 11,726
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624
Role of the microbiota in immunity and inflammation.
Belkaid, Y., & Hand, T. W. (2014) · Cell · doi:10.1016/j.cell.2014.03.011 · Cited by 5,385
Metagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699
Cited by
Items 201–300 of 991
Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
Xu, Y., Fu, Y., Zhu, B., Wang, J., & Zhang, B. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02023 · Cited by 94
“Besides, a lack of genetic pathways involved in polyamine transport and B vitamin biosynthesis was associated with an increased risk of colitis (22).”
BackgroundGreten, T. F., Abou‐Alfa, G. K., Cheng, A., Duffy, A. G., El-Khoueiry, A. B., Finn, R. S., Galle, P. R., Goyal, L., He, A. R., Kaseb, A. O., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002794 · Cited by 82
Giordan, Q., Salleron, J., Vallance, C., Moriana, C., & Clément-Duchêne, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.716317 · Cited by 84
“The Bacteroidetes phylum could play an immunomodulating role, enhancing the differentiation of naïve T cells into Treg cells, thus reducing colitis (34).”
BackgroundNi, J., Zhang, Z., Ge, M.-J., Chen, J., & Zhuo, W. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00953-z · Cited by 88
Manasson, J., Wallach, D. S., Guggino, G., Stapylton, M., Badri, M. H., Solomon, G. E., Reddy, S. M., Coras, R., Aksenov, A. A., Jones, D. R., et al. (2019) · Arthritis & Rheumatology · doi:10.1002/art.41169 · Cited by 84
Microbiota as a mediator of cancer progression and therapy
Pope, J. L., Tomkovich, S., Yang, Y., & Jobin, C. (2017) · Translational Research · doi:10.1016/j.trsl.2016.07.021 · Cited by 79
“Consistent with this observation, high abundance of gut bacteria belonging to the bacteroidetes phylum correlated with resistance to CTLA-4-blockade–induced colitis in patients.(116) Thus, supplementation of B.”
Passat, T., Touchefeu, Y., Gervois, N., Jarry, A., Bossard, C., & Bennouna, J. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.07.005 · Cited by 88
“[26] Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al.”
BackgroundKhan, Z., Hammer, C., Guardino, E., Chandler, G. S., & Albert, M. L. (2019) · Genome Medicine · doi:10.1186/s13073-019-0652-8 · Cited by 85
Yue, M., Tao, Y., Fang, Y., Lian, X., Zhang, Q., Xia, Y., Wei, Z., & Dai, Y. (2019) · The FASEB Journal · doi:10.1096/fj.201900425rr · Cited by 82
Gastrointestinal adverse events associated with immune checkpoint inhibitor therapy
Rajha, E., Chaftari, P. S., Kamal, M. J., Maamari, J., Chaftari, C. P., & Yeung, S. J. (2019) · Gastroenterology report · doi:10.1093/gastro/goz065 · Cited by 76
Tonneau, M., Elkrief, A., Pasquier, D., del Socorro, T. P., Chamaillard, M., Bahig, H., & Routy, B. (2020) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2020.10.033 · Cited by 78
The gut microbiome and efficacy of cancer immunotherapy
Roviello, G., Iannone, L. F., Bersanelli, M., Mini, E., & Catalano, M. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107973 · Cited by 84
Shaikh, F. Y., Gills, J. J., & Sears, C. L. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.08.076 · Cited by 77
“[16] Dubin K, Callahan MK, Ren B, Khanin R, Viale A, Ling L, et al.”
BackgroundPulmonary toxicity of immune checkpoint immunotherapy
Ghanbar, M., & Suresh, K. S. (2024) · Journal of Clinical Investigation · doi:10.1172/jci170503 · Cited by 88
Toxicity in the era of immune checkpoint inhibitor therapy
Keam, S., Turner, N., Kugeratski, F. G., Rico, R., Colunga-Minutti, J., Poojary, R., Alekseev, S., Patel, A. B., Li, Y. J., Sheshadri, A., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1447021 · Cited by 92
“Furthermore, the Bacteroidaceae, Rikenellaceae , and Barnesiellaceae families have been associated with resistance to the development of ICI-colitis (124).”
BackgroundImmune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation
Yang, H., Yao, Z., Zhou, X., Zhang, W., Zhang, X., & Zhang, F. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108377 · Cited by 81
Lessons from CTLA-4 deficiency and checkpoint inhibition
Lo, B., & Abdel‐Motal, U. M. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.07.014 · Cited by 86
Leite, M. L., da Cunha, N. B., & Costa, F. F. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.10.010 · Cited by 75
“It seems that shifts in gut bacteria were related to increased anticancer immunotherapeutic treatment and also with toxicity to gastric and intestinal epithelium cells of patients administered with the antibody (Dubin et al., 2016).”
Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response?
Sharma, A., Buschmann, M. M., & Gilbert, J. A. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1437 · Cited by 86
Usyk, M., Pandey, A., Hayes, R. B., Moran, U., Pavlick, A. C., Osman, I., Weber, J. S., & Ahn, J. (2021) · Genome Medicine · doi:10.1186/s13073-021-00974-z · Cited by 81
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
“Bacteroidetes phylum Melanoma CTLA4 inhibitor ↓ colitis [45]”
BackgroundCheckpoint inhibitor hepatotoxicity: pathogenesis and management
Cunningham, M. E., Gupta, R., & Butler, M. O. (2023) · Hepatology · doi:10.1097/hep.0000000000000045 · Cited by 82
Bai, L., Zhou, P., Li, D., & Ju, X. (2017) · Journal of Medical Microbiology · doi:10.1099/jmm.0.000568 · Cited by 81
“Bacteroidales are enriched in many pathogenic settings, such as hepatitis C [42], colitis [43] and colorectal cancer [44], and in patients after cholecystectomy [45], and revealed the link between GI microbiota and immunodeficiency or malnutrition.”
BackgroundAdverse events induced by immune checkpoint inhibitors
Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 81
“Microbiome • Baseline microbiome enriched for Faecalibacterium predictive of colitis [43] • Abundance of Bacteroidetes phylum may be protective for development of colitis [44]”
BackgroundCancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
Frankel, A. E., Deshmukh, S. K., Reddy, A., Lightcap, J., Hayes, M., McClellan, S. B., Singh, S., Rabideau, B. D., Glover, T. G., Roberts, B., et al. (2019) · Integrative Cancer Therapies · doi:10.1177/1534735419846379 · Cited by 76
Immune Checkpoint Inhibitor–Mediated Diarrhea and Colitis: A Clinical Review
Gong, Z., & Wang, Y. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00002 · Cited by 75
Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 81
Lin, A., Jiang, A., Huang, L., Yu, H., Zhang, C., Zhu, L., Mou, W., Liu, Z., Zhang, J., Cheng, Q., et al. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2452277 · Cited by 81
“62,63 Bacteroides has also exhibited similar bidirectional effects.”
Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation
Sun, J., Song, S., Liu, J., Chen, F., Li, X., & Wu, G. (2025) · npj Biofilms and Microbiomes · doi:10.1038/s41522-025-00678-x · Cited by 89
“…the incidence of colitis after anti-CTLA-4 therapy in melanoma patients, while the presence of Fusobacterium and other Firmi-cutes makes immunotherapy-associated colitis more frequent in such patients, this is mediated by ICOS-induced increases in CD4 + T cell levels and sCD25 levels 46,47 .”
A Blueprint to Advance Colorectal Cancer Immunotherapies
Le, D. T., Hubbard-Lucey, V. M., Morse, M. A., Heery, C. R., Dwyer, A., Marsilje, T. H., Brodsky, A. N., Chan, E., Deming, D. A., Diaz, L. A., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0375 · Cited by 69
“In melanoma patients treated with ipilimumab, the presence of the Bacteroidetes phylum in feces correlated with resistance to the development of checkpoint blockade–induced colitis (68).”
BackgroundJoachim, L., Göttert, S., Sax, A., Steiger, K., Neuhaus, K., Heinrich, P., Fan, K., Orberg, E. T., Kleigrewe, K., Ruland, J., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104834 · Cited by 74
“25,29 Currently, no obvious pattern among the phylogeny has emerged that would correlate with bacterial species and how they in fl uence cancer therapeutic responses.”
BackgroundCargo transport shapes the spatial organization of a microbial community
Shrivastava, A., Patel, V. K., Tang, Y., Yost, S. C., Dewhirst, F. E., & Berg, H. C. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1808966115 · Cited by 68
“The Bacteroidetes represent about half of the bacterial population of the human gut microbiome (15, 16) and changes in their concentration correlates with diseases such as obesity, diabetes and colitis (17-19).”
BackgroundStrategies to Improve the Efficacy of Dendritic Cell-Based Immunotherapy for Melanoma
Hargadon, K. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01594 · Cited by 69
“Together, these insights will be important for the optimization of strategies to manipulate the gut microbiome in ways that enhance antitumor immune reactivity while also minimizing adverse events such as therapy-associated colitis (202).”
BackgroundProbiotic species in the modulation of the anticancer immune response
Marinelli, L., Tenore, G. C., & Novellino, E. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.08.007 · Cited by 64
Shi, W., Shen, L., Zou, W., Wang, J., Yang, J., Wang, Y., Liu, B., Xie, L., Zhu, J. Y., & Zhang, Z. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.562463 · Cited by 74
Byrd, A. L., Liu, M., Fujimura, K. E., Lyalina, S., Nagarkar, D. R., Charbit, B., Bergstedt, J., Patin, E., Harrison, O. J., Quintana-Murci, L., et al. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20200606 · Cited by 63
A Novel Putrescine Exporter SapBCDF of Escherichia coli
Sugiyama, Y., Nakamura, A., Matsumoto, M., Kanbe, A., Sakanaka, M., Higashi, K., Igarashi, K., Katayama, T., Suzuki, H., & Kurihara, S. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.762450 · Cited by 64
Jia, W., Cheng, L., Tan, Q., Liu, Y., Dou, J., Yang, K., Yang, Q., Wang, S., Li, J., Niu, G., et al. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1188229 · Cited by 72
“Network module was divided according to previous literatures (Faust et al., 2012; Williams et al., 2014; Dubin et al., 2016).”
MethodIntestinal microbiota: a novel perspective in colorectal cancer biotherapeutics
Ding, C., Tang, W., Fan, X., & Wu, G. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s170626 · Cited by 69
“In addition, it had shown that increased representation of Bacteroidetes was correlated with resistance to the development of CTLA-4 blockade-induced colitis.(159) In addition to CTLA-4, another immune-checkpoint inhibitor, PD-1, could bind to tumor cell surface receptor PD-L1, sensitize PD-1/ PD-L1 signaling pathway,…”
Adverse events associated with immune checkpoint inhibitor treatment for cancer
Esfahani, K., Meti, N., Miller, W. H., & Hudson, M. (2019) · Canadian Medical Association Journal · doi:10.1503/cmaj.180870 · Cited by 65
Liu, W., Ma, F., Sun, B., Liu, Y., Tang, H., Luo, J., Chen, H., & Luo, Z. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.756872 · Cited by 77
“Higher abundance of Bacteroidetes in the phylum level was widely evidenced in patients who did not develop ICI colitis (29).”
BackgroundGut microbiome for predicting immune checkpoint blockade-associated adverse events
Hu, M., Lin, X., Sun, T., Shao, X., Huang, X., Du, W., Guo, M., Zhu, X., Zhou, Y., Tong, T., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01285-9 · Cited by 77
“…(https:// www. ncbi. nlm . nih . gov / biopr oject/ PRJNA 762360) for McCulloch et al. [20], PRJNA379764 (https:// www. ncbi. nlm. nih . gov / biopr oject/ PRJNA 379764) for Chaput et al. [34], and PRJNA302832 (https:// www. ncbi. nlm. nih . gov/ biopr oject/ PRJNA 302832) for Dubin et al. [35].”
BackgroundResultGut Microbiome Modulates Response to Cancer Immunotherapy
Khan, M. A. W., Ologun, G. O., Arora, R., McQuade, J. L., & Wargo, J. A. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06111-x · Cited by 75
Shah, K. P., Song, H., Ye, F., Moslehi, J. J., Balko, J. M., Salem, J.-E., & Johnson, D. B. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0986 · Cited by 64
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.006 · Cited by 63
Intestinal Microbiota Predicts Lung Cancer Patients at Risk of Immune-Related Diarrhea
Liu, T., Xiong, Q., Li, L., & Hu, Y. (2019) · Immunotherapy · doi:10.2217/imt-2018-0144 · Cited by 69
Oh, B., Boyle, F. M., Pavlakis, N., Clarke, S. J., Eade, T., Hruby, G., Lamoury, G., Carroll, S. L., Morgia, M., Kneebone, A. B., et al. (2021) · Cancers · doi:10.3390/cancers13194824 · Cited by 78
“They reported that a higher relative abundance of bacteria belonging to the Bacteroidetes phylum was correlated with resistance to the development of ICIs-induced colitis [22].”
BackgroundMolecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances
Kim, H. J., & Kim, Y. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25052984 · Cited by 83
“Furthermore, vemurafenib, the first BRAF inhibitor approved by the FDA in 2011 for metastatic melanoma with the BRAF V600E mutation, has demonstrated an increase in OS compared with dacarbazine in a phase III (BRIM-3) trial [63–66].”
BackgroundTargeting the Gut Microbiome to Mitigate Immunotherapy-Induced Colitis in Cancer
Chang, A. E., Golob, J. L., Schmidt, T. M., Peltier, D. C., Lao, C. D., & Tewari, M. (2021) · Trends in Cancer · doi:10.1016/j.trecan.2021.02.005 · Cited by 62
Early melanoma invasivity correlates with gut fungal and bacterial profiles
Vitali, F., Colucci, R., Paola, M. D., Pindo, M., Filippo, C. D., Moretti, S., & Cavalieri, D. (2021) · British Journal of Dermatology · doi:10.1111/bjd.20626 · Cited by 67
Intestinal toxicity to CTLA-4 blockade driven by IL-6 and myeloid infiltration
Zhou, Y., Medik, Y. B., Patel, B., Zamler, D. B., Chen, S., Chapman, T., Schneider, S. M., Park, E. M., Babcock, R. L., Chrisikos, T. T., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20221333 · Cited by 65
“Quality-filtered sequences with >97% identity were processed with the Divisive Amplicon Denoising Algorithm 2 generating amplicon sequence variants that were classified with the SILVA v138 (Callahan et al., 2016; Quast et al., 2013).”
Immune checkpoint blockade for hematologic malignancies: a review
Pianko, M. J., Liu, Y., Bagchi, S., & Lesokhin, A. M. (2017) · Stem Cell Investigation · doi:10.21037/sci.2017.03.04 · Cited by 69
“Early data in melanoma suggests gut microbiota may play a role in development of colitis, however for the most part predictors of toxicity from immune checkpoint inhibitors are lacking (110).”
BackgroundZhang, Z., He, S., Cao, X., Ye, Y., Yang, L., Wang, J., Liu, H., & Sun, H. (2019) · Journal of Functional Foods · doi:10.1016/j.jff.2019.103729 · Cited by 65
Prevotella copri is associated with carboplatin-induced gut toxicity
Yu, C., Zhou, B., Xia, X., Chen, S., Deng, Y., Wang, Y., Wu, L., Tian, Y., Zhao, B., Xu, H., et al. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1963-9 · Cited by 66
Imbalance in the Gut Microbiota of Children With Autism Spectrum Disorders
Ding, H., Yi, X., Zhang, X., Wang, H., Liu, H., & Mou, W.-W. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2021.572752 · Cited by 74
“org 7 deficiency or malnutrition diseases, such as colitis, hepatitis, and bowel cancer (Keren et al., 2015; Aly et al., 2016; Dubin et al., 2016).”
BackgroundAdverse Events in Cancer Immunotherapy
Abdel‐Wahab, N., Alshawa, A., & Suarez-Almazor, M. E. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-53156-4_8 · Cited by 69
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 68
“This reactive colitis is also accompanied by elevated humoral responses to enteric flora and decreased in Bacteriodetes species.[158, 159] Similar observations of”
Longo, V., Brunetti, O., Azzariti, A., Galetta, D., Nardulli, P., Leonetti, F., & Silvestris, N. (2019) · Cancers · doi:10.3390/cancers11040539 · Cited by 66
“phylum was correlated with a low incidence of checkpoint-block-induced colitis [17].”
BackgroundMangan, B. L., McAlister, R. K., Balko, J. M., Johnson, D. B., Moslehi, J. J., Gibson, A., & Phillips, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14433 · Cited by 65
“In melanoma patients treated with CTLA-4 inhibitors, those who were colitis-free were noted to have an abundance of Bacteroides and an increase in the expression of genetic pathways involved in polyamine transport and vitamin B synthesis.(92) To further characterize the effects of the microbiome on toxicity, 2 studies…”
BackgroundMechanism of Idiosyncratic Drug Induced Liver Injury (DILI): Unresolved Basic Issues
Teschke, R., & Uetrecht, J. (2021) · Annals of Translational Medicine · doi:10.21037/atm-2020-ubih-05 · Cited by 58
“There is also evidence that endotoxins, such as LPS derived from the gut microbiome, enter the hepatic blood vessels through a leaky gut, and if not cleared by the liver, reach the systemic circulation where they can be quantified (66-69).”
BackgroundMicrobiota transplantation: Targeting cancer treatment
Wu, X., Zhang, T., Chen, X., Ji, G., & Zhang, F. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.03.010 · Cited by 67
Schett, A., Rothschild, S. I., Fontecedro, A. C., Krähenbühl, S., Früh, M., Schmid, S., Driessen, C., & Joerger, M. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03993-1 · Cited by 67
Dutta, D., & Lim, S. H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00211-6 · Cited by 64
“Similarly, melanoma patients with increased abundance of Bacteroidaceae, Rikenellaceae, and Barnesiellaceae members responded better to CTLA-4 antibodies [88].”
BackgroundGut Microbiota in Lung Cancer: Where Do We Stand?
Georgiou, K. E., Marinov, B. I., Farooqi, A. A., & Gazouli, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910429 · Cited by 65
“ICI administration usually has gastrointestinal and hepatic complications, such as hepatitis, diarrhea, and enterocolitis, as a result of a complicated interchange mechanism between host genetics, immune responses, the environment, and the microbiota [105].”
BackgroundRoles of microbiota in response to cancer immunotherapy
Inamura, K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.026 · Cited by 65
The tumor organismal environment: Role in tumor development and cancer immunotherapy
Dieterich, L. C., & Bikfalvi, A. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.12.021 · Cited by 68
“Furthermore, the risk of checkpoint inhibitor-induced colitis in melanoma patients may be predicted by the gut microbiome (122, 123).”
BackgroundSignificance of human microbiome in breast cancer: Tale of an invisible and an invincible
Chadha, J., Nandi, D., Atri, Y., & Nag, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.010 · Cited by 63
Emerging biomarkers for cancer immunotherapy in melanoma
Axelrod, M. L., Johnson, D. B., & Balko, J. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.09.004 · Cited by 61
Nutraceuticals in colorectal cancer: A mechanistic approach
Rossi, M., Mirbagheri, S., Keshavarzian, A., & Bishehsari, F. (2018) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2018.06.027 · Cited by 63
“(Dubin et al., 2016), which suggests a potential implication of microbial targeted interventions in modulating the side effects from immunotherapy.”
BackgroundThe role of the bacterial microbiome in the treatment of cancer
Yu, Z., Xie, R., You, R., Liu, Y., Chen, X.-Y., Chen, M., & Huang, P.-Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08664-0 · Cited by 62
“inhibitors in metastatic melanoma (MM) patients in several studies [13, 14, 20, 41] and may decrease the response rate and attenuate systemic and antitumour”
BackgroundGarcia-Neuer, M. I., Marmarelis, M. E., Jangi, S., Luke, J. J., Ibrahim, N., Davis, M., Weinberg, J., Donahue, H., Bailey, N., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0302 · Cited by 59
“A prospective cohort study analyzing inflammatory markers, such as calprotectin, lactoferrin, M2-PK, and S100A12, as well as a microbiome panel analysis of patients who have gastrointestinal symptoms and those who develop immune-related colitis, would be useful in understanding the biological mechanisms of inflammatio…”
BackgroundProphylactic probiotics for cancer therapy-induced diarrhoea: a meta-analysis
Wardill, H. R., Sebille, Y. Z. A. V., Ciorba, M. A., & Bowen, J. M. (2018) · Current Opinion in Supportive and Palliative Care · doi:10.1097/spc.0000000000000338 · Cited by 61
The Role of the Microbiome in Drug Response
Pryor, R. E., Martínez‐Martínez, D., Quintaneiro, L. M., & Cabreiro, F. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023612 · Cited by 59
Ding, S., Ma, Y., Liu, G., Yan, W., Jiang, H., & Fang, J. Q. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.01152 · Cited by 67
“These findings provide new insights into the treatment of IBD because the intestinal microbiota plays an important role in intestinal inflammatory responses, including changes in the relative abundance and diversity of intestinal microbiota immunity (Lepage et al., 2011; Dubin et al., 2016).”
BackgroundImpact of the Gut Microbiome on Immune Checkpoint Inhibitor Efficacy—A Systematic Review
Pierrard, J., & Seront, E. (2019) · Current Oncology · doi:10.3747/co.26.5177 · Cited by 64
Kim, K. H., Hur, J. Y., Cho, J., Ku, B. M., Koh, J., Koh, J., Sun, J., Lee, S., Ahn, J. S., Park, K., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1722023 · Cited by 67
Gut microbiota: impacts on gastrointestinal cancer immunotherapy
Lau, H. C.-H., Sung, J. J. �., & Yu, J. Q. (2021) · Gut Microbes · doi:10.1080/19490976.2020.1869504 · Cited by 59
“blockade-induced colitis.(32) Later in 2019, a similar study also reported the enriched fecal abundance of Bacteroides and Parabacteroides from phylum Bacteroidetes in 18 pembrolizumab-treated lung cancer patients without the development of blockadeinduced diarrhea.”
BackgroundResultMicrobiota modulate Doxorubicin induced cardiotoxicity
An, L., Wuri, J., Zheng, Z., Li, W., & Yan, T. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105977 · Cited by 61
Novel strategies for modulating the gut microbiome for cancer therapy
Cho, Y. S., Han, K., Xu, J., & Moon, J. J. (2024) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2024.115332 · Cited by 65
“For example, Faecalibacterium , Clostridia , and Escherichia have been reported to be positively associated with ICIs-induced colitis, whereas Bacteroidetes and Bifidobacterium were negatively associated with ICIs-induced colitis [202].”
The Human Microbiota and Prostate Cancer: Friend or Foe?
Massari, F., Mollica, V., Nunno, V. D., Gatto, L., Santoni, M., Scarpelli, M., Cimadamore, A., López-Beltrán, A., Cheng, L., Battelli, N., et al. (2019) · Cancers · doi:10.3390/cancers11040459 · Cited by 62
Huang, J., Jiang, Z., Wang, Y., Fan, X., Cai, J., Yao, X., Liu, L., Huang, J., He, J., Xie, C., et al. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.06.004 · Cited by 60
Yang, M., Wang, Y., Yuan, M., Tao, M., Kong, C., Li, H., Tong, J., Zhu, H., & Yan, X. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106876 · Cited by 63
Keller, H. R., Zhang, X., Li, L., Schaider, H., & Wells, J. W. (2017) · Oncotarget · doi:10.18632/oncotarget.18523 · Cited by 58
“Another recent study evaluating the influence of the intestinal microbiome on immunotherapyrelated colitis found that increased Bacteroides representation within the gut correlated with resistance to anti-CTLA-4-induced colitis [44].”
BackgroundHuang, C.-L., Li, M., Liu, B., Zhu, H., Dai, Q., Fan, X., Mehta, K. D., Huang, C. H., Neupane, P. C., Wang, F., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.642110 · Cited by 68
“Of note, the documented AEs in that three studies (17, 20, 21) were virtually all irAEs.”
BackgroundEmerging clinical relevance of microbiome in cancer: promising biomarkers and therapeutic targets
Dai, J.-H., Tan, X.-R., Qiao, H., & Liu, N. (2023) · Protein & Cell · doi:10.1093/procel/pwad052 · Cited by 59
“The phyla Firmicutes and Bacteroidetes are the dominant bacteria in healthy gut, and the ratio of them is usually regarded as a mark of host health (Yu et al., 2017).”
BackgroundInfluentialBotticelli, A., Zizzari, I. G., Mazzuca, F., Ascierto, P. A., Putignani, L., Marchetti, L., Napoletano, C., Nuti, M., & Marchetti, P. (2016) · Oncotarget · doi:10.18632/oncotarget.12985 · Cited by 60
“Moreover a recent study established that microbiota composition enriched in Bacteroides phlilym can prevent the onset of immune colitis in patients treated with anti-CTLA-4 (Ipilimumab) [66].”
BackgroundLang, N., Dick, J., Slynko, A., Schulz, C., Dimitrakopoulou‐Strauss, A., Sachpekidis, C., Enk, A., & Hassel, J. C. (2019) · Immunotherapy · doi:10.2217/imt-2018-0146 · Cited by 57
Cho, Y. K., & Jung, C. H. (2023) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2023.0072 · Cited by 62
Cao, C., Yue, S., Lü, A., & Liang, C. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107321 · Cited by 67
Ubiquitin Ligases in Cancer Immunotherapy – Balancing Antitumor and Autoimmunity
Fujita, Y., Tinoco, R., Li, Y., Senft, D., & Ronai, Z. A. (2019) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2019.02.002 · Cited by 58
“The gut microbiome may help in predicting IRAE emergence after ICB treatment: select commensal Bacteroidetes strains were shown to elicit protective effects against CTLA-4-blockadeinduced colitis [97], and transfer of bifidobacteria to anti-CTLA-4-treated mice mitigates colitis independently of antitumor immunity [98].”
BackgroundLin, L., Xiong, J., Liu, L., Wang, F., Cao, W., & Xu, W. (2023) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2023.167499 · Cited by 59
Fucoidan enhances the anti-tumor effect of anti-PD-1 immunotherapy by regulating gut microbiota
Li, H., Dong, T., Tao, M., Zhao, H., Lan, T., Yan, S., Gong, X., Hou, Q., Ma, X., & Song, Y. (2024) · Food & Function · doi:10.1039/d3fo04807a · Cited by 55
Aziz, R. K., Hegazy, S. M., Yasser, R., Rizkallah, M. R., & ElRakaiby, M. T. (2018) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2018.1530216 · Cited by 56
“colitis suggesting their possible protective role on the colon through polyamine transport and vitamin B biosynthesis [99].”
BackgroundOvercoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies
Puccini, A., Battaglin, F., Iaia, M. L., Lenz, H., & Salem, M. E. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000404 · Cited by 55
Abdelrahim, M., Mamlouk, O., Lin, H. Y., Lin, J. S., Page, V. D., Abdel‐Wahab, N., Swan, J. T., Selamet, U., Yee, C., Diab, A. K., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1927313 · Cited by 53
“Several papers have evaluated irAEs, and further studies of genetic predisposition and perturbations in microbiota environment are under way.(40,41) However, in relation to comorbidities associated with other irAEs, autoimmune disease has been well recognized as a risk factor for irAEs;(35)”
BackgroundNeurologic immune-related adverse events associated with adjuvant ipilimumab: report of two cases
Garcia, C. A., El-Ali, A., Rath, T. J., Contis, L. C., Gorantla, V. C., Drappatz, J., & Davar, D. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0393-z · Cited by 52
Severe Epididymo-Orchitis and Encephalitis Complicating Anti-PD-1 Therapy
Quach, H. T., Robbins, C. T., Balko, J. M., Chiu, C. Y., Miller, S. A., Wilson, M. R., Nelson, G. E., & Johnson, D. B. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0722 · Cited by 61
The impact of tumor and gut microbiotas on cancer therapy: Beneficial or detrimental?
Hekmatshoar, Y., Saadat, Y. R., Khatibi, S. M. H., Özkan, T., Vahed, F. Z., Nariman‐Saleh‐Fam, Z., Gargari, B. P., Sunguroğlu, A., & Vahed, S. Z. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.116680 · Cited by 56
Kang, B. W., & Chau, I. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000791 · Cited by 55
Feakins, R. M., Torres, J., Borralho, P., Burisch, J. M., Gonçalves, T. C., de Ridder, L., Driessen, A. L. C., Lobatón, T., Menchen, L. A., Mookhoek, A., et al. (2021) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjab141 · Cited by 65
Metadata
- Authors
- Dubin, K., Callahan, M. K., Ren, B., Khanin, R., Viale, A., Ling, L., No, D., Gobourne, A., Littmann, E., Huttenhower, C., Pamer, E. G., & Wolchok, J. D.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Harvard University (US)
- Broad Institute (US)
- Corresponding author
- Pamer, Eric G.
- Wolchok, Jedd D.
- ORCID
- Venue
- Nature Communications
- Published
- 2016-02-02
- Volume
- 7
- Issue
- 1
- Pages
- 10391-10391
- ISSN
- 2041-1723 (ISSN-L)
- PMC
- PMC4740747
- OpenAlex
- W2275606382
- Cited by
- 987
- References
- 40
- Citations by year
- 2026: 56 · 2025: 76 · 2024: 83 · 2023: 117 · 2022: 145 · 2021: 128 · 2020: 131 · 2019: 112 · 2018: 71 · 2017: 48 · 2016: 19
- FWCI
- 43.32
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Bristol-Myers Squibb
- Memorial Sloan-Kettering Cancer Center (P30 CA008748)
- Tow Foundation
- National Institutes of Health
- Weill Cornell Medical College
- National Cancer Institute (P30CA008748)
- National Institute of General Medical Sciences (T32GM007739)
- National Institute of Allergy and Infectious Diseases (R01 AI42135, R01AI042135)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- ipilimumab, CTLA-4, metastatic melanoma, gut microbiota, Bacteroidetes, immune-related adverse events, cancer immunotherapy, polyamine transport, B vitamin biosynthesis, biomarkers, inflammatory bowel disease
- MeSH terms
- Gastrointestinal Microbiome, Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Bacteroidaceae, Colitis, Female, Humans, Male, Melanoma, Middle Aged, Prospective Studies, Risk Factors, RNA, Ribosomal, 16S, Skin Neoplasms, Sequence Analysis, RNA, Bacteroidetes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.